Alector’s stock ended Friday at $1.81, down 42.7% over the past year. Monday morning, Genentech put $100 million upfront on a Parkinson’s program that has not yet entered the clinic. Vaxcyte had the busier day: Phase 3 data before the open, a $1 billion financing after the close.
Alector Licenses AL050 to Genentech for $100 Million Upfront
Alector, Inc. (Nasdaq: ALEC) granted Genentech exclusive worldwide rights to AL050 on October 5, taking $100 million upfront with up to $1.17 billion more tied to development, regulatory and commercial milestones, plus tiered royalties. AL050 pairs an engineered glucocerebrosidase (GCase), an enzyme that clears fats building up in brain cells, with Alector’s Brain Carrier platform, built to move drugs across the blood-brain barrier. The target is Parkinson’s disease tied to GCase deficiency, most pronounced in GBA1 mutation carriers.
It has not reached patients. Alector’s CEO described the program as moving toward the clinic.
Shares surged 72% in premarket trading, then traded up about 22% in early trading. Before the deal, the stock closed at $1.81 on October 2, a market cap near $203 million.
Genentech takes over development, manufacturing and commercialization. Alector keeps the Brain Carrier platform and says the cash stretches its runway into 2029. It needed the help. GSK sent notice in July terminating their collaboration, effective January 2, 2027, after the Phase 3 INFRONT-3 trial of latozinemab missed its co-primary endpoint in October 2025.
Satellos Fills Duchenne Trial, Secures Forazapadin Patent to 2044
Satellos Bioscience Inc. (TSX: MSCL; Nasdaq: MSLE) completed enrollment on September 30 in BASECAMP, its Phase 2 trial of forazapadin in boys aged 7 to 10 with Duchenne muscular dystrophy. It beat its target in under nine months. Topline data is due in the first quarter of 2027.
Boys were randomized 1:1:1 to 60 mg, 120 mg or placebo across 18 sites. Primary endpoints are safety, tolerability and muscle force measured by dynamometry. Forazapadin is an oral pill targeting AAK1, a protein Satellos links to muscle repair, and works independently of dystrophin, so exon mutation status does not limit who could take it.
On October 5 the USPTO issued a composition of matter patent covering forazapadin through September 6, 2044, with a possible extension after any U.S. approval.
No BASECAMP efficacy data exists yet, and forazapadin is investigational. Satellos has also had a US$50 million at-the-market share facility in place since August. Market cap sat near $180 million on October 5.
Vaxcyte Hits Phase 3 Endpoints for VAX-31, Then Launches $1B Raise
Vaxcyte, Inc. (Nasdaq: PCVX) reported on October 5 that VAX-31 met all prespecified primary endpoints in OPUS-1, the pivotal adult Phase 3 trial of its 31-valent pneumococcal conjugate vaccine (PCV). The trial dosed 4,047 participants. All 28 serotypes shared with Prevnar 20 and/or Capvaxive met noninferiority, meaning immune responses were not meaningfully weaker than the comparator. The three serotypes only VAX-31 covers, plus cross-reactive 20B, met superiority.
One line in the release deserves more attention than the headline. Against Capvaxive alone, serotypes 3 and 12F missed the 0.667 noninferiority bar and cleared only the looser historical 0.5 threshold, a key secondary endpoint. Vaxcyte’s own chief scientific officer expects the Capvaxive comparison to be a particular focus of FDA review.
Shares rose roughly 32% in early trading, from a pre-data market cap of about $8.4 billion. After the close, Vaxcyte launched $500 million in stock and pre-funded warrants plus $500 million in convertible notes due 2032. VAX-31 remains investigational. OPUS-2 and OPUS-3 read out in the first half of 2027, with a BLA submission planned for the first half of 2028.
ALEC, MSLE, PCVX: Forward-Looking FAQ
No. Those payments only come if AL050 hits development, regulatory and commercial targets, and Alector’s 8-K states Genentech may terminate the license for convenience on prior written notice.
The primary endpoints are safety, tolerability and muscle force by dynamometry. Satellos says BASECAMP could support FDA talks on a potential accelerated pathway, but that is the company’s view, not an agency position.
Unknown. Both met the historical 0.5 threshold, but Vaxcyte itself expects the Capvaxive comparison to draw FDA scrutiny, and OPUS-2 and OPUS-3 data arrive first, in the first half of 2027.
Sources
- GlobeNewswire / The Manila Times: Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy, October 5, 2026
- SEC EDGAR: Alector, Inc. Form 8-K, Genentech License Agreement, October 5, 2026
- SEC EDGAR: Alector, Inc. Form 8-K, GSK Agreement termination notice, July 6, 2026
- Reuters via Yahoo Finance: Alector soars as Roche licenses Parkinson’s therapy for up to $1.27 billion, October 5, 2026
- GuruFocus: Alector (ALEC) Shares Jump 22% on Genentech Licensing Deal for AL050 Program, October 5, 2026
- StockTitan: Alector (ALEC) Stock Price, News & Analysis
- GlobeNewswire: Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin, September 30, 2026
- RTTNews: Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD, September 30, 2026
- GlobeNewswire: Satellos Granted Composition of Matter Patent for Forazapadin, October 5, 2026
- CNN Markets: Satellos Bioscience (MSLE) news, including US$50 million at-the-market facility
- Stockrow: Satellos Bioscience (MSLE) market data, October 5, 2026
- SEC EDGAR: Vaxcyte, Inc. Form 8-K Exhibit 99.1, Positive Topline Data from OPUS-1, October 5, 2026
- GuruFocus: Vaxcyte (PCVX) Shares Jump 32% on Positive Phase 3 VAX-31 Trial Results, October 5, 2026
- Investing.com: Vaxcyte announces $1 billion dual public offering, October 5, 2026
- CNN Markets: Vaxcyte (PCVX) market data
Editorial Disclosure
Sources: SEC Form 8-K filings, company press releases via GlobeNewswire, named financial press. Securities discussed: Alector, Inc. (Nasdaq: ALEC), Satellos Bioscience Inc. (TSX: MSCL; Nasdaq: MSLE), and Vaxcyte, Inc. (Nasdaq: PCVX). aktiego.com has received no compensation from any company, IR firm, or third party mentioned. No aktiego.com staff or principal holds a position in ALEC, MSCL/MSLE, or PCVX. Release dates verified: Alector October 5, 2026; Satellos September 30 and October 5, 2026; Vaxcyte October 5, 2026. Alector: AL050 has not entered clinical trials; milestone payments are contingent; Genentech may terminate for convenience; GSK collaboration terminates effective January 2, 2027. Satellos: forazapadin is investigational; no BASECAMP efficacy data yet; US$50 million at-the-market facility in place. Vaxcyte: market cap approximately $8.4 billion before the October 5 data; VAX-31 is investigational with no FDA approval; serotypes 3 and 12F missed the prespecified individual noninferiority criterion versus PCV21; $1 billion stock, pre-funded warrant and convertible note offering launched October 5, dilutive to existing shareholders. All three companies are unprofitable and depend on continued access to capital. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
